US allows increased production of Takeda’s ADHD drug to address shortage
Sept 4 (Reuters) - The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's (4502.T), opens new tab ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing shortage in the United States. The raised production limit follows the Food and Drug Administration's request in July, the DEA said in a notice on Tuesday.
Other Articles in this Edition
US allows increased production of Takeda’s ADHD drug to address shortage
Study reveals slight increase in ADHD risk from prenatal cannabis exposure
Rising number of women diagnosed with ADHD as adults
Adolescents with smaller amygdala region of the brain have higher risk of developing ADHD
Higher ADHD diagnosis and prescriptions for children born in July and August, research finds
Navigating ADHD Treatment Amid the Rise of Social Media and Self-Diagnosis
Study links melatonin secretion to ADHD symptoms in children
An Artist’s Guide to ADHD and Getting Stuff Done
How Much Does Special Education Truly Cost? Finally, an Answer Is on the Horizon